FDA Approves Voceryq, a DNA Immunotherapy for RRP

VoceryqWhat to know

30-second read

For Otolaryngology (ENT)

Who

Adults with HPV-6/11 recurrent respiratory papillomatosis needing frequent surgical debulking — trial entry required ≥2 surgeries in the prior year.

What’s new

Voceryq (INO-3107), a plasmid DNA immunotherapy against HPV-6/11 given by intramuscular injection with electroporation — Inovio’s first FDA approval.

Evidence

Accelerated approval from a single-arm, 32-patient trial: complete surgery-free response in 28% at 1 year, rising to 50% at 2 years.

Big advantage

A non-surgical option for a disease managed almost entirely by repeat operating-room debulking; most responders needed markedly fewer procedures.

Key consideration

Approved on uncontrolled, single-arm data; FDA requires a confirmatory trial. 41% had injection-site pain or fatigue; no boxed warning on file.

Availability

Approved 30 October 2026. No price, launch date or payer coverage announced; dosing logistics for referring practices not yet public.

Practice impactConsider for selected patients

A genuine non-surgical option for the RRP patient cycling through repeat debulking, but the evidence is early, uncontrolled and not yet compared head-to-head with Papzimeos — weigh the accelerated-approval caveat before switching a stable patient.

Read the full physician analysis

Full analysis · 8 min readFDA approval notice, 30 Oct 2026 · ClinicalTrials.gov NCT04398433 · Papzimeos approval, Aug 2025

The U.S. Food and Drug Administration granted accelerated approval on 30 October 2026 to Voceryq (INO-3107), a plasmid DNA immunotherapy from Inovio Pharmaceuticals for adults with recurrent respiratory papillomatosis (RRP) — the company’s first FDA-approved product in three decades of development, and only the second approved therapy for a disease that, until August 2025, had none.

A disease measured in trips to the OR

RRP is driven almost entirely by HPV-6 and HPV-11, and its hallmark is not a single diagnosis but a schedule: wart-like papillomas regrow on the larynx and airway faster than they can be definitively removed, so the only established treatment has been repeat surgical debulking — microlaryngoscopy with a laser or microdebrider, often every few months, sometimes more often in aggressive disease. Patients in Voceryq’s pivotal trial averaged four surgeries a year before enrolling; some had as many as eight. There has never been an FDA-approved medical therapy to break that cycle until Papzimeos (Precigen) arrived in August 2025. Voceryq is the second attempt, built on a different platform and a slightly less restrictive trial population.

What is actually in the injection

Voceryq is a plasmid DNA immunotherapy: a circular piece of engineered DNA encoding HPV-6/11 antigens, injected intramuscularly and paired with a brief pulse of electroporation from Inovio’s proprietary CELLECTRA device, which opens muscle-cell membranes long enough for the plasmid to enter and be expressed. The goal is to train the immune system to recognize and clear HPV-infected cells in the airway — an approach with no viral vector and no lipid nanoparticle, which Inovio has pursued across its DNA-medicines pipeline for years without a prior approval. The exact dosing schedule referring physicians will need to plan around — number of injections, interval, and who administers the electroporation step — has not yet been made public; that detail should come with the product’s full prescribing information at launch.

The evidence behind the number

Accelerated approval rests on RRP-001 (ClinicalTrials.gov NCT04398433), an open-label, single-arm Phase 1/2 trial of 32 adults with HPV-6/11-confirmed RRP who needed at least two surgeries in the year before enrolling. There was no control arm and no randomization — the comparison is each patient against their own surgical history, not against a placebo or an untreated cohort. Long-term follow-up reported a complete response — zero surgeries in the following 12 months — in 28% of patients at year one, rising to 50% at year two, with an overall response (a 50% or greater reduction in surgical frequency) in 72% at year one and 86% at year two. Mean annual surgeries fell from 4.1 before treatment to 0.9 at two years. Those are real, clinically meaningful numbers for patients who were otherwise on a fixed surgical schedule — but they come from an uncontrolled trial with no independent arm to rule out a treatment-unrelated change in disease course, which is exactly why FDA used the accelerated pathway rather than full approval and is requiring a confirmatory trial before the question is settled.

Two approved RRP therapies, built differently

	Voceryq (Inovio)	Papzimeos (Precigen)
U.S. status	Accelerated approval, 30 Oct 2026; confirmatory trial required	Full approval, 14 Aug 2025; no confirmatory trial required
Platform	Plasmid DNA immunotherapy with CELLECTRA electroporation	Non-replicating adenoviral vector expressing an HPV-6/11 antigen
Administration	Intramuscular injection paired with electroporation	Four subcutaneous injections over 12 weeks
Trial eligibility	Adults needing ≥2 surgeries in the prior year (RRP-001, n=32)	Adults needing ≥3 surgeries in the prior year (n=35)
Reported response	Complete response 28% (yr 1) → 50% (yr 2); overall response 72–86%	Complete response 51% (18/35) at 12 months

Neither trial was controlled or randomized, and the two were not run head-to-head against each other or against a shared comparator; eligibility thresholds differed, so the response rates are not directly comparable. Prescribe from the current labels.

Safety signals so far

In RRP-001, 41% of patients (13 of 32) had a treatment-related adverse event, most commonly transient injection-site pain (31%) and fatigue (9%); no treatment-related serious adverse events were reported, and the events described were predominantly low-grade. No boxed warning appears in the materials available at approval. That is a reassuring early profile for an injectable immunotherapy, but it comes from the same small, uncontrolled trial as the efficacy numbers — a confirmatory trial, once it enrolls, is also where a rarer safety signal would be more likely to surface.

Coverage and access: the open question

Inovio has not announced a list price, a launch date or any payer engagement for Voceryq. Because the product is not yet on the market, there is no coding, prior-authorization or site-of-care guidance to report — and because this is an accelerated approval with a confirmatory trial pending, some payers may apply additional scrutiny before covering it compared with a fully approved therapy. Practices referring patients for Voceryq should expect a period before price and access are settled, consistent with Papzimeos’s own rollout after its August 2025 approval.

What changes at the referral desk

• Patient selection. The evidence base is adults with HPV-6/11-confirmed RRP and a documented pattern of frequent surgery — RRP-001 enrolled patients needing two or more procedures a year. There is no pediatric or juvenile-onset data to extend the discussion to that population.
• Choosing between Voceryq and Papzimeos. The two have not been compared head-to-head; a laryngologist weighing them today is weighing platform, dosing schedule and approval status (full vs. accelerated), not a validated efficacy ranking.
• Setting expectations. A complete response at two years in half of patients is meaningful, but it is a single-arm result; frame it to patients as promising and early, not proven.
• Confirmatory-trial awareness. If a confirmatory trial opens, enrollment may be the most direct way to generate the controlled evidence this disease has never had.
• Access planning. With no price or payer decision yet public, counsel patients that timing to first dose may depend on insurance review once the product reaches pharmacies.

The honest read is that RRP now has two approved non-surgical options where, fourteen months ago, it had none — and that is a genuine shift for a disease otherwise managed by the calendar of the operating room. What Voceryq has not yet earned is proof beyond a single uncontrolled trial, a defined place relative to Papzimeos, or a settled path to a patient’s pharmacy. Every story on this desk is filed by specialty on the For Physicians front.

How RRP went from no approved therapy to two

1. Sep 2023

   Breakthrough Therapy Designation

   FDA designates INO-3107 a Breakthrough Therapy for recurrent respiratory papillomatosis.

2. 14 Aug 2025

   Papzimeos approved

   Precigen's adenoviral-vector immunotherapy becomes the first FDA-approved RRP therapy, under full approval.

3. 30 Oct 2026

   FDA approves Voceryq

   Accelerated approval for adults with RRP; Inovio's first approved product.

4. Ahead

   Confirmatory trial

   Required to convert accelerated approval to full approval; protocol and timeline not yet public.

Frequently asked questions

How does Voceryq differ from Papzimeos, the other approved RRP therapy?

Different platforms and different trial populations. Voceryq is a plasmid DNA immunotherapy delivered by intramuscular injection with brief electroporation; Papzimeos (Precigen) is a non-replicating adenoviral-vector immunotherapy given as four subcutaneous injections over 12 weeks. Voceryq's pivotal trial enrolled adults needing at least 2 surgeries a year; Papzimeos required at least 3. The trials were not head-to-head, so the two response rates are not directly comparable.

Does accelerated approval mean the benefit is confirmed?

No. Accelerated approval lets FDA clear a drug on a response measure reasonably likely to predict clinical benefit, ahead of confirmatory proof. Voceryq's approval rests on a single-arm, 32-patient trial with no control group; FDA has required a confirmatory trial as a condition of approval, and Inovio has not yet published its protocol or timeline.

What still isn't known about Voceryq?

Price, launch date and payer coverage are all unannounced. Durability beyond two years of follow-up, performance in patients who have already tried Papzimeos, and the confirmatory trial's design are all open questions. Treat the complete-response rates as early and unvalidated by a controlled trial.